Journal article
Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures
Current opinion in urology, Vol.14(5), pp.271-275
09/2004
DOI: 10.1097/00042307-200409000-00005
PMID: 15300147
Abstract
To give an update on the new modalities in treating patients with superficial bladder cancer who have failed bacille Calmette-Guérin.
The addition of interferon to bacille Calmette-Guérin has proven to be an effective combination therapy for bacille Calmette-Guérin failures. Electromotive intravesical mitomycin C as well as local microwave hyperthermia have been shown to improve drug delivery and increase response rates. Intravesical gemcitabine has shown some promising results in phase I studies and is being investigated in phase II trials. Photodynamic therapy is proposed as a second-line therapy for bacille Calmette-Guérin failures.
New treatment modalities are being introduced and existing ones improved to treat bacille Calmette-Guérin-refractory superficial bladder cancer. These agents need to be studied in large randomized trials. Until these agents prove to decrease recurrence rates and delay progression of high-risk superficial bladder cancer, cystectomy remains the standard of care for the patient who is a good surgical candidate and willing to undergo such major surgery.
Details
- Title: Subtitle
- Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures
- Creators
- Fadi N Joudi - Department of Urology, University of Iowa, Iowa City, 200 Hawkins Drive, IA 52242, USAMichael A O'Donnell
- Resource Type
- Journal article
- Publication Details
- Current opinion in urology, Vol.14(5), pp.271-275
- Publisher
- United States
- DOI
- 10.1097/00042307-200409000-00005
- PMID
- 15300147
- ISSN
- 0963-0643
- eISSN
- 1473-6586
- Language
- English
- Date published
- 09/2004
- Academic Unit
- Urology
- Record Identifier
- 9984051532702771
Metrics
8 Record Views